TipRanks
Go Ultimate55% OFF

Bolt Biotherapeutics (BOLT) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Bdc-4182Gastroesophageal Adenocarcinoma, Gastric Cancer Adenocarcinoma Metastaticphase1AndPhase2RecruitingA First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal CancerApr 04, 2025―
Pertuzumab, Bdc-1001Metastatic Breast Cancer, Her2-Positive Breast CancerPhase IITerminatedTrial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast CancerJun 23, 2023―
Nivolumab, Bdc-1001Her2-Positive Breast Cancer, Her2-Positive Solid Tumors, Her2-Positive Colorectal Cancer, Her2-Positive Gastroesophageal Cancer, Her2-Positive Endometrial Cancerphase1AndPhase2TerminatedA First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid TumorsFeb 12, 2020―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Bolt Biotherapeutics, Inc. (BOLT) have in its pipeline
Bolt Biotherapeutics BOLT is currently developing the following drugs: Bdc-4182, Pertuzumab, Bdc-1001, Nivolumab, Bdc-1001. These drug candidates are in various stages of clinical development as the company works toward FDA approval.